## Core Concept
Hybridoma technology is a method used to produce large quantities of monoclonal antibodies. It involves the fusion of an antibody-producing B cell with a myeloma (cancer) cell that can grow indefinitely in the lab. This fusion cell, or hybridoma, can produce large quantities of a single type of antibody.

## Why the Correct Answer is Right
The correct answer is related to the characteristics and applications of hybridoma technology. Monoclonal antibodies produced by hybridomas are identical and target a specific antigen. They are used in research, diagnostics, and therapy due to their high specificity.

## Why Each Wrong Option is Incorrect
**Option A:** This option is not provided, but typically, correct statements about hybridoma technology include its use in producing monoclonal antibodies for therapeutic and diagnostic purposes.

**Option B:** Similarly, this option is not provided, but correct statements might involve the process of creating hybridomas, which includes fusing B cells with myeloma cells.

**Option C:** Without the specific details of option C, it's hard to address directly, but generally, hybridoma technology is indeed used for producing monoclonal antibodies.

**Option D:** This option is marked as the correct answer, implying it contains an incorrect statement about hybridoma technology.

## Clinical Pearl / High-Yield Fact
A key point to remember is that hybridoma technology allows for the production of **monoclonal antibodies**, which are crucial in targeted therapies and have revolutionized the treatment of various diseases, including cancers and autoimmune disorders.

## Correct Answer Line
**Correct Answer: D.**